jeudi 20 octobre 2016

Onco Actu du 20 octobre 2016

1. Biologie

Science Snaps: how knowing the shape of cancer cells could improve treatments [Cancer Research UK]

3.1 Tabac

Tobacco companies 'exaggerating need for small retailers to sell cigarettes' [Cancer Research UK]

Big Tobacco sees its future in cigarettes, not vaping [The Conversation]

3.3 Prévention - Vaccins

Preteens need only two HPV shots — not three, government panel says [STAT]

CDC calls on doctors to pitch HPV shots as cancer prevention, not STD protection [FiercePharma]

CDC now recommends just two HPV vaccine doses for preteens [Washington Post]

Children 14 or Under Need Fewer H.P.V. Vaccine Doses [NY Times]

HPV vaccine access easier for US preteens after panel ruling [The Guardian]

Pre-teens need only two HPV shots, not three, CDC recommends [Reuters]

5. Traitements

Seven of the most promising new approaches in cancer treatment [The Institute of Cancer Research]

5.12 Immunothérapies

Merck gets first-line NSCLC guideline as Bristol, Roche denied [FierceBiotech]

All In One Place: A New Immuno-Oncology Trial Resource [Xconomy]

Investigational Immunotherapy Was Safe, Tolerable, and Showed Some Activity Against Melanoma [AACR]

5.12.2 Immunothérapies - CAR-T

Scientists engineer an extra control into CAR T-cell therapy [FierceBiotech]

5.2 Pharma

Liver tox cases force Daiichi Sankyo to curtail recruitment for PhIII trial of a ‘breakthrough’ drug [EndPoints]

5.2.1 Pharma - Partenariats

Novartis partners with tiny microcap Cerulean as it nabs $20M [FierceBiotech]

5.2.3 Pharma - économie

Roche third-quarter sales rise 3 percent, confirms outlook [Reuters]

5.3 Traitements - FDA, EMA, NICE...

Regulatory Flexibility and Lessons Learned: Drugs for Rare Diseases [FDA]

5.3.4 Traitements - AMM (FDA, EMA)

FDA Modifies Use of Erlotinib in NSCLC to Include Only Patients Whose Tumors Harbor EGRF Mutations [ASCO]

FDA Approves Lilly's LARTRUVO™ (olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma [Lilly]

FDA grants accelerated approval to new treatment for advanced soft tissue sarcoma [FDA]

Eli Lilly wins a quick OK for new sarcoma drug olaratumab [EndPoints]

FDA grants accelerated approval to Lilly's soft tissue sarcoma drug [Reuters]

5.4 Traitements - Economie

Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology [JAMA]

6.5 Médecines alternatives

The Texas Medical Board vs. Stanislaw Burzynski, round ∞: Will Burzynski slither away yet again? [Respectful Insolence]

6.7 DMP, Big Data & applis

The Cure for Cancer Is Data—Mountains of Data [Wired]